Abstract
Polymorphic variants of CYP1A2 and CYP2D6 genes of the cytochrome P450 system were studied in patients with schizophrenia with drug-induced motor disorders and hyperprolactinemia against the background of long-term neuroleptic therapy. We revealed an association of polymorphic variant C-163A CYP1A2*1F of CYP1A2 gene with tardive dyskinesia and association of polymorphic variant 1846G>A CY2D6*4 and genotype A/A of CYP2D6 gene (responsible for debrisoquin-4-hydroxylase synthesis) with limbotruncal tardive dyskinesia in patients with schizophrenia receiving neuroleptics for a long time.
| Original language | English |
|---|---|
| Pages (from-to) | 1-4 |
| Number of pages | 4 |
| Journal | Bulletin of Experimental Biology and Medicine |
| DOIs | |
| Publication status | Accepted/In press - 29 Mar 2016 |
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Fingerprint Dive into the research topics of 'CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects'. Together they form a unique fingerprint.
Cite this
Ivanova, S. A., Filipenko, M. L., Vyalova, N. M., Voronina, E. N., Pozhidaev, I. V., Osmanova, D. Z., Ivanov, M. V., Fedorenko, O. Y., Semke, A. V., & Bokhan, N. A. (Accepted/In press). CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. Bulletin of Experimental Biology and Medicine, 1-4. https://doi.org/10.1007/s10517-016-3250-4